Immunology of Diabetes

Marta Vives-Pi

The multidisciplinary Immunology of Diabetes Group at the IGTP is part of the Immunology Section of the Germans Trias i Pujol University Hospital (HUGTiP). It is made up of researchers, endocrinologists, paediatricians and technicians; the group works to understand more about the causes of type 1 diabetes. The research of the group is focused on translational research: Immunotherapies for the prevention and treatment of Type 1 diabetes, pathogenic mechanisms of autoimmunity and paediatric type 1 diabetes: tolerance, spontaneous remission and biomarkers. Their goal is to contribute to therapeutic intervention in type 1 diabetes and other autoimmune diseases.

The principal investigator, Marta Vives-Pi (MSc, PhD), has been working in the field of autoimmune diseases since 1988. Since 1996 she has been leading different research projects, with special emphasis on the development of experimental immunotherapies. In 2000 she started the specific pathogen free Unit (SPF) at the IGTP for the study of experimental models of type 1 diabetes. M. Vives-Pi is also the co-founder and Scientific Director of Ahead Therapeutics SL a spin-off company set up to transfer the immunotherapy technology generated by the group to the clinical arena and convert know-how into treatments for autoimmune diseases such as type 1 diabetes and multiple sclerosis.

Group Members

Marta Vives-Pi, mvives(ELIMINAR), Group Leader and PI
Silvia Rodríguez-Fernández,srodriguez(ELIMINAR), Postdoctoral Investigator
David Perna-Barrulldperna(ELIMINAR), Postdoctoral Investigator
Rosa M Ampudiarampudia(ELIMINAR), Research Technician
Laia Gómez-Muñoz, lgomez(ELIMINAR), Predoctoral Investigator


See Publications Marta Vives-Pi

Grup Vives 2016.02.08

Research lines

Immunotherapies for the prevention and treatment of type 1 diabetes

The line of research aims to stop the autoimmune response using innovative therapies to re-establish the cellular tolerance of the insulin-producing cells.

Pathogenic mechanisms of autoimmunity

This line of research aims to identify the mechanisms of the specific immune responsible for destruction of insulin-producing beta cells, with special atention to prenatal environmental factors.

Pediatric type 1 diabetes: tolerance, spontaneous remission and biomarkers

The aim of this line is to explore mechanisms of tolerance restablishment in children at the onset of the disease, and to define new biomarkers of remission.


Valorización de una terapia antígeno-específica para el tratamiento disruptivo de la diabetes tipo 1; esclerosis múltiple, miastenia gravis, enfermedad celíaca

Code: CPP2021-008475
Principlal Investigator: Marta Vives-Pi  
Start Date: 10/02/2022
End Date: 31/12/2025

Proyecto CPP2021-008475 del proyecto de investigación financiado por:

Proyecto CPP2021-008475 de investigación financiado por MCIN/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR

A new dawn for type 1 diabetes: Combining a nanotherapy to halt autoimmunity with beta-cell regeneration

Code: 201632_10
Principlal Investigator Marta Vives-Pi  
Start Date: 01/03/2017
End Date: 29/02/2020


Biomarcadores de remisión parcial en pacientes con diabetes tipo 1. Aplicación en monitorización inmunológica y ensayos clínicos

Biomarkers of partial remission in patients with type 1 diabetes for immune-monitoring and intervention trials

Code: PI18/00436
Principal Investigator: Marta Vives-Pi  
Start Date: 01/01/2019
End Date: 31/12/2021

Terapia contra la autoinmunidad para la prevención y la curación de la diabetes tipo 1. Nanopartículas tipo liposoma que re-educan el sistema inmunológico para permitir la regeneración de las células beta

Code: Cer001
Principle Investigator: Marta Vives-Pi        
Start Date: 01/06/2017
End Date: 31/05/2019



Code: CB15/00071
Principle Investigator: Didac Mauricio        
Start Date: 2015


Spin-off  Company

Member of the Working Group Pancreatic Islets of the Spanish Diabetes Society



The podcast 'Un bri de ciència' explores type 1 diabetes in its second episode

The new episode of the podcast 'Un bri de ciència' is presented under the title "La diabetis tipus 1: quan la defensa t'ataca" (Type 1 diabetes: when your defences attack you). Researcher Marta Vives Pi explains the problems of autoimmune diseases, with an emphasis on type 1 diabetes.

Studying partial remission of type 1 diabetes in children: New biomarkers and the immunoregulatory role of microRNA

A study led by researchers from IGTP's Immunology of Diabetes group has identified new microRNA as biomarkers for the partial remission phase, also known as "honeymoon phase", of type 1 diabetes, and has linked the miR-30d-5p microRNA to immunoregulatory processes that may take place during this phase.

More information


Marta Vives-Pi, PhD, Principal Investigator

(+34) 93 033 05 25